Founded in 1992; offers biologics and liposome/LNP development and manufacturing, with an officially disclosed Austrian pharmaceutical manufacturing authorization.
AustriaFull profile →
Company database
Profiles, sources, and comparisons are open. Choose a field on the left to see its companies.
Search & refine Filters update automatically
Disease tags identify mentions in recorded facts or pipeline text, not approved indications or a complete pipeline. Platform service providers may have no disease-specific tag.
471 matching companiesShowing 24 / 471
Offers MicroED structure services for drugs, PROTACs, natural products, and small protein crystals.
ChinaFull profile →
Focuses on nucleic acid delivery platforms and intellectual property licensing; its LNP technology supports partner mRNA, RNA editing, and in vivo CAR-T programs.
CanadaFull profile →
Explicitly offers small-molecule MicroED and presents protein and peptide MicroED examples, separately from SPA services.
China / United StatesFull profile →
Offers IVT mRNA-LNP development and manufacturing, with SMARTCAP capping and STLNP delivery technologies.
South KoreaFull profile →
The life science business of Germany's Merck KGaA offers mRNA, lipid, LNP, fill-finish, and testing services. It is separate from U.S.-based Merck & Co. / MSD.
GermanyFull profile →
Offers mRNA design, manufacturing, and LNP formulation, with disclosed partner work on tissue- and cell-targeted delivery.
NetherlandsFull profile →
Offers lipid- and polymer-based nonviral delivery systems, LNP/PNP formulation optimization, and manufacturing for mRNA and other nucleic acid payloads.
SpainFull profile →
Offers mRNA production services. In 2025 the company announced Belgian regulatory approval of an expanded mRNA manufacturing facility for late-stage clinical and commercial production.
BelgiumFull profile →
Founded in 2021, the company offers DNA, RNA, LNP/tLNP, analytical, and GMP manufacturing services for advanced-therapy CMC development.
ChinaFull profile →
Offers mRNA DNA templates, IVT and HiXCap capping, purification, LNP formulation, and aseptic fill-finish, and supplies nucleic acid raw materials.
ChinaFull profile →
GenScript's life science business offers IVT RNA and LNP-related services. Its ProBio subsidiary provides CGT CMC services including mRNA vaccines and nucleic acid drugs. Entity information uses GenScript group-level data.
United States / ChinaFull profile →
The Toyama site in Japan offers integrated GMP mRNA production, LNP formulation, and fill-finish. It is distinct from FUJIFILM Biotechnologies (formerly Diosynth).
JapanFull profile →
A Japanese CMC contract research company combining solid-form selection with high-throughput nucleation, competitive slurry conversion, and structure determination.
JapanFull profile →
An original October 2026 investor record identifies oral cyclic peptides as a priority business and states that orders have been received. Only manufacturing services are recorded; proprietary drug pipelines are not inferred.
ChinaFull profile →
Offers mRNA development and manufacturing, with co-located mRNA, LNP, and fill-finish capabilities supporting RNA drug supply.
United StatesFull profile →
The TIDES platform covers process development, analytics, and manufacturing for monocyclic, polycyclic, and modified peptides. This review did not confirm a named oral cyclic peptide program.
ChinaFull profile →
Offers LNP development and manufacturing for mRNA and other biological payloads, using processes including microfluidics, impingement mixing, filtration, and concentration.
GermanyFull profile →
Clinical CRO services include operations, regulatory affairs, pharmacovigilance, data management and statistics, SMO, and laboratories. Frontage is consolidated.
ChinaFull profile →
WuXi Biologics offers Biologics structure, higher-order structure, potency, release and stability. This is the analytical service business of an integrated CRO/CDMO.
China / United States / Germany / 爱尔兰Full profile →
Founded in 2007, the company offers cell-free enzymatic dbDNA templates for mRNA and other genetic medicines. This is an upstream template service, not equivalent to an mRNA-LNP drug product CDMO.
United KingdomFull profile →
Offers xRNA and LNP services, including mRNA drug substance, LNPs, and ATMP fill-finish. The current provider, brand, and manufacturing site require confirmation.
SwedenFull profile →
In 2023 Daiichi Sankyo announced Japanese approval of its DAICHIRONA (DS-5670) mRNA COVID-19 vaccine. The approved product should be evaluated separately from other newer programs.
JapanFull profile →
The company's first mRNA Japanese encephalitis vaccine, GBP560, entered Phase 1/2 trials in Australia and New Zealand. It is distinct from its existing non-mRNA vaccines.
South KoreaFull profile →
Coverage expands from sourced records; this database does not claim all biopharma companies.